Login
$DYN
$16.75 -$0.41 (2.39%) Live

$DYN 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -

29 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

29 Jul 2026 8-K: Results of Operations and Financial Condition

- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -

22 Jul 2026 8-K: Entry into a Material Definitive Agreement; Other Events

18,300,000 Shares of Common Stock, par value $0.0001 per share

20 Jul 2026 8-K: Other Events

On July 20, 2026, Dyne Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its biologics license application (“BLA”) for zeleciment rostudirsen (z-rostudirsen, also know...

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to ...

17 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On June 16, 2026 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the Second Amendment (the “Second Amendment”) to its Loan and Security Agreement with Hercules Capital, Inc., in its capacity as admini...

08 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2026, Dyne Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The following is a summary of the matters voted on at the 2026 Annual Meeting.

03 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

11 May 2026 8-K: Results of Operations and Financial Condition

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -

02 Mar 2026 8-K: Results of Operations and Financial Condition

- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Advancing Clinically Validated Platform Toward Commercialization 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | JANUARY 2026

23 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 22, 2025, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Vikram Karnani as a Class II director...

10 Dec 2025 8-K: Entry into a Material Definitive Agreement; Other Events

18,980,478 Shares of Common Stock, par value $0.0001 per share

08 Dec 2025 8-K: Creation of a Direct Financial Obligation

On December 8, 2025 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the First Amendment (the “First Amendment”) to Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”), in its capacity...

08 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

05 Nov 2025 8-K: Results of Operations and Financial Condition

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 ...

02 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On October 1, 2025, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Brian Posner as a Class III director to...

04 Aug 2025 8-K: Regulation FD Disclosure; Other Events

- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 -

28 Jul 2025 8-K: Results of Operations and Financial Condition

- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 -

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support